1-(8-氮杂双环[3.2.1]辛-8-基)乙酮 | 769-04-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 中文名称: 1-(8-氮杂双环[3.2.1]辛-8-基)乙酮
• 英文名称: N-Acetyl-nortropan
• 英文别名: 1-(8-azabicyclo[3.2.1]octan-8-yl)ethanone
• CAS: 769-04-0
• 化学式: C₉H₁₅NO
• 分子量: 153.224
• InChiKey: DBLLJXWLRNHLAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-Cycloheptyl-acetamid 在 calcium hydroxide 、 lithium bromide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.0h， 以13.4%的产率得到1-(8-氮杂双环[3.2.1]辛-8-基)乙酮
  参考文献：
  名称：

  Elofson, Richard M.; Gadallah, Fahmi F.; Laidler, James K., Canadian Journal of Chemistry, 1987, vol. 65, p. 2770 - 2773

  摘要：

  DOI：

文献信息

• Tyrosine Kinase Inhibitor And Uses Thereof
  申请人：Xuanzhu Pharma Co., Ltd.

  公开号：US20170112833A1

  公开（公告）日：2017-04-27

  Disclosed is a compound of Formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, or their stereoisomers, which can be used as tyrosine kinase inhibitor. Also disclosed is a method for preparing the compound, a pharmaceutical composition and a kit comprising the compound, and uses of the compound. The compound can be used as tyrosine kinase inhibitor, or can be used to reduce or inhibit activity of EGFR or mutant thereof, such as EGFR mutant comprising T790M mutation, in a cell, or to treat and/or prevent a disease associated with overactivity of EGFR, such as cancer.

  公开了一种公式(I)的化合物或其药物可接受的盐、酯或溶剂，或它们的立体异构体，可用作酪氨酸激酶抑制剂。还公开了制备该化合物的方法、包含该化合物的药物组合物和套件，以及该化合物的用途。该化合物可用作酪氨酸激酶抑制剂，或可用于减少或抑制细胞中EGFR或其突变体的活性，例如包含T790M突变的EGFR突变体，或用于治疗和/或预防与EGFR过度活动相关的疾病，如癌症。
• [EN] TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
  申请人：CTXT PTY LTD

  公开号：WO2016034673A1

  公开（公告）日：2016-03-10

  A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式I的化合物，其中：n为1或2；p为0或1；R1可选地为一个或多个卤素或甲基基团；R2a和R2b分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4为H或Me；R5为H或Me；R6a和R6b分别选自H和Me；A为(i)可选地取代的苯基；(ii)可选地取代的萘基；或(iii)可选地取代的C5-12杂环基。
• METHODS FOR ONE-POT N-DEMETHYLATION/N-ACYLATION OF MORPHINE AND TROPANE ALKALOIDS
  申请人：Carroll Robert James

  公开号：US20090005565A1

  公开（公告）日：2009-01-01

  The present invention provides a method for the N-demethylation and/or N-acylation of an N-methylated heterocycle such as morphine alkaloids or tropane alkaloids. The method comprises reacting the heterocycle with an acylating agent in the presence of a metal catalyst.

  本发明提供了一种用于对N-甲基杂环化合物（如吗啡生物碱或曲梨生物碱）进行N-去甲基化和/或N-酰化的方法。该方法包括在金属催化剂存在下将杂环化合物与酰化剂反应。
• [EN] PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS<br/>[FR] ANALOGUES DE PYRIDONEMORPHINANE ET ACTIVITÉ BIOLOGIQUE SUR DES RÉCEPTEURS DES OPIOÏDES
  申请人：PURDUE PHARMA LP

  公开号：WO2014091295A1

  公开（公告）日：2014-06-19

  The application is directed to compounds of Formula (I-A) and pharmaceutically acceptable salts and solvates thereof, wherein Formula (II), R1a, R2a, R3a, R4 and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.

  该应用程序涉及公式（I-A）的化合物及其药用可接受的盐和溶剂化合物，其中公式（II），R1a，R2a，R3a，R4和Za的定义如规范所述。该发明还涉及使用公式I-A的化合物来治疗对调节一个或多个阿片受体敏感的疾病，或作为合成中间体。本发明的某些化合物特别适用于治疗疼痛。
• [EN] PRMT5 INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5
  申请人：CTXT PTY LTD

  公开号：WO2017153518A1

  公开（公告）日：2017-09-14

  A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, -NH2, -C(=O)NH2, and -CH2OH; R4b is either H or Me; X is either N or CH; R7 is selected from H and C1-4 alkyl; (a) one of R8a, R8b, R8c and R8d is selected from H, halo, C1-4 alkyl, C1-4 alkoxy, NHC1-4 alkyl; (b) another of R8a, R8b, R8c and R8d is selected from H, C1-4 alkyl, C1-4 fluoroalkyl, C3-6 cycloalkyl, C5-6 heteroaryl, C5-6 heteroaryl methyl, C4-6 heterocyclyl, C4-6 heterocyclyl methyl, phenyl, benzyl, halo, amido, amidomethyl, acylamido, acylamidomethyl, C1-4 alkyl ester, C1-4 alkyl ester methyl, C1-4 alkyl carbamoyl, C1-4 alkyl carbamoyl methyl, C1-4 alkylacyl, C1-4 alkylacyl methyl, phenylcarbonyl, carboxy, carboxymethyl, ether, amino, amino methyl, sulfonamido, sulfonamino, sulfone, sulfoxide, nitrile and nitrilemethyl; (c) the others of R8a, R8b, R8c and R8d are H.

  化合物的化学式(Ia)，(Ib)或(Ic)，其中：n为1或2；RN为H或Me；R1是可选择的一个或多个卤素或甲基基团；R2a和R2b分别从以下组中选择：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d（如果存在）分别从以下组中选择：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别从H和Me中选择；R4a从OH，-NH2，-C(=O)NH2和-CH2OH中选择；R4b为H或Me；X为N或CH；R7从H和C1-4烷基中选择；(a)R8a，R8b，R8c和R8d中的一个从H，卤素，C1-4烷基，C1-4烷氧基，NHC1-4烷基中选择；(b)R8a，R8b，R8c和R8d中的另一个从H，C1-4烷基，C1-4氟代烷基，C3-6环烷基，C5-6杂环芳基，C5-6杂环芳基甲基，C4-6杂环烷基，C4-6杂环烷基甲基，苯基，苄基，卤素，酰胺基，酰胺基甲基，酰胺基，酰胺基甲基，C1-4烷基酯，C1-4烷基酯甲基，C1-4烷基氨基，C1-4烷基氨基甲基，C1-4烷基酰基，C1-4烷基酰基甲基，苯基羰基，羧基，羧甲基，醚，氨基，氨基甲基，磺酰胺基，磺酰氨基，砜，亚砜，腈和腈甲基中选择；(c)R8a，R8b，R8c和R8d中的其他为H。